Pharming (PHAR) Equity Income (2019 - 2025)
Historic Equity Income for Pharming (PHAR) over the last 7 years, with Q3 2025 value amounting to -$37000.0.
- Pharming's Equity Income rose 9162.9% to -$37000.0 in Q3 2025 from the same period last year, while for Sep 2025 it was -$2.0 million, marking a year-over-year increase of 300.0%. This contributed to the annual value of -$1.8 million for FY2024, which is 50899.65% down from last year.
- According to the latest figures from Q3 2025, Pharming's Equity Income is -$37000.0, which was up 9162.9% from $8000.0 recorded in Q2 2025.
- Pharming's 5-year Equity Income high stood at $991000.0 for Q2 2022, and its period low was -$1.8 million during Q4 2024.
- In the last 5 years, Pharming's Equity Income had a median value of -$250000.0 in 2025 and averaged -$167767.0.
- Its Equity Income has fluctuated over the past 5 years, first skyrocketed by 112051.16% in 2021, then tumbled by 50830.45% in 2024.
- Over the past 5 years, Pharming's Equity Income (Quarter) stood at -$82000.0 in 2021, then soared by 637.8% to $441000.0 in 2022, then crashed by 165.53% to -$289000.0 in 2023, then plummeted by 508.3% to -$1.8 million in 2024, then surged by 97.9% to -$37000.0 in 2025.
- Its Equity Income was -$37000.0 in Q3 2025, compared to $8000.0 in Q2 2025 and -$250000.0 in Q1 2025.